GlobeNewswire Inc | May 26, 2021 08:01AM EDT

May 26, 2021

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Adrian Gottschalk, President and Chief Executive Officer, will present at two upcoming investor conferences.

Events:

Jefferies Virtual Healthcare ConferenceFormat: Presentation and 1x1sTuesday, June 1, 202110:00am ET

Goldman Sachs 42nd Annual Healthcare Conference Format: Fireside Chat and 1x1sTuesday, June 8, 20218:00am ET

A live webcast of both presentations can be accessed under Events & Presentations in the Investors section of the Companys website, www.foghorntx.com.

About Foghorn Therapeutics

Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

Media Contact:

Fanny Cavali, Foghorn Therapeuticsfcavalie@foghorntx.com

Gregory Kelley, Ogilvygregory.kelley@ogilvy.com

Investor Relations Contact:

Allan Reine, Foghorn Therapeuticsareine@foghorntx.com

Hans Vitzthum, LifeSci Advisors617-430-7578hans@lifesciadvisors.com